Compare VTSI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTSI | ANL |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 350.9M |
| IPO Year | 1999 | 2022 |
| Metric | VTSI | ANL |
|---|---|---|
| Price | $4.20 | $9.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $16.00 |
| AVG Volume (30 Days) | 26.2K | ★ 218.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $16,524,225.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.39 | N/A |
| P/E Ratio | $45.89 | ★ N/A |
| Revenue Growth | ★ 5.57 | N/A |
| 52 Week Low | $3.57 | $0.88 |
| 52 Week High | $7.47 | $12.09 |
| Indicator | VTSI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 57.38 |
| Support Level | N/A | $1.37 |
| Resistance Level | $5.15 | $10.15 |
| Average True Range (ATR) | 0.21 | 0.92 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 20.38 | 60.88 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.